Hummingbird Express Website: www.hummingbirdexpress.com.au

A service of Hummingbird Insight Pty Ltd ABN: 64612454823

Website: www.hummingbirdinsight.com.au

Affiliated with Hummingbird Advisory Healthcare Professional Panel

Website: www.hummingbirdadvisory.com.au

Effective Date: 27/03/2026

Introduction

These Terms and Conditions (“Terms”) govern access to and use of the Hummingbird Express website and services (“Platform”).

Hummingbird Express is a subscription-based online service providing clients (“Users”) with access to validated Healthcare Professionals (“HCPs”) for the purpose of submitting questions and receiving personalised, experience-based responses.

By accessing or using the Platform, you agree to be bound by these Terms. If you do not agree, you must not use the Platform.

Nature of the Service

Hummingbird Express provides an agile and cost-effective alternative to traditional market research by enabling client users to submit targeted questions directly to qualified Healthcare Professionals.

Healthcare Professionals will:

1. Be selected by the client user based on HCP type (and up to three sub-quotas/specialties). Sub-quota options include Specialty type, Therapy area (where applicable), State and Region.
2. An SMS and an email will be sent to the first 5 HCPs listed who meet the criteria. It will include the question summary.
3. If an HCP receives an invitation to participate, they have up to 24 hours to respond – either “not this time” or “accept”. Once accepted the HCP has up to 12 hours from acceptance to respond to the question.
4. No additional screening questions will be required.
5. Once logged in, the HCP will access the question, which may include a piece of material to review (up to 2 pages and max 2 MB).
6. The HCP can choose to reply to or refuse the question once they have reviewed it.
7. The first 3 HCPs to reply to the initial question will begin a ‘chat’ with the client.
8. If any HCPs have not yet responded, they will receive a message notifying them the question has closed.
9. Responses will be completed in a chat interface similar to those used in other applications and websites, and may be accessed on a mobile phone, tablet, laptop, or PC.
10. The client may ask up to 3 additional questions for clarification on the initial response – but not introduce a new subject.
11. The process will take no more than 20 minutes of your time.
12. Both parties are expected to respond to any follow-up queries in a timely manner and at the earliest reasonable opportunity. Once an initial response is received each party has up to 1 business day to make or respond to any follow up query.
13. Once the question is marked as ‘complete’ by the client, or if no response is received by the client within 2 business days, the will be updated and the honoraria allocated to the HCP’s account.
14. Your funds can be accumulated or cashed out using Electronic Funds Transfer (EFT) or E-Gift Card: https://www.giftpay.com.au/business/egifts.aspx

Healthcare Professional honoraria

Reimbursement for taking part will be according to FMV and paid per completed question (including the additional queries).

Honoraria will be paid per completed question (including any permitted follow-up queries) in accordance with fair market value (FMV).

Honoraria funds can be accumulated or cashed out using Electronic Funds Transfer (EFT) or E-Gift Card: https://www.giftpay.com.au/business/egifts.aspx

User Obligations

All Users agree that they will:

• Use the Platform for lawful commercial or research purposes only.
• Comply with all applicable pharmaceutical industry regulations and ethical marketing standards.
• Any information presented and subjects discussed are not intended to be promotional and the honorarium you are entitled to is not dependent on whether you provide positive or negative responses.

Client Users are solely responsible for ensuring their questions comply with Therapeutic Goods Administration (TGA) requirements and Medicines Australia Code of Conduct obligations (where applicable).

Healthcare Professional Participation

HCPs participating on the Platform:

• Are validated by Hummingbird Insight prior to participation.
• Provide responses based on their professional experience and opinion.
• Are not acting as agents, representatives, or spokespersons for Hummingbird Express.

HCP responses represent individual professional opinions only and do not constitute clinical advice, regulatory advice, or endorsement.

No Medical or Regulatory Advice

Hummingbird Express provides access to professional opinion for insight purposes only.

Responses:

• Do not constitute medical advice.
• Must not be used for direct patient care decisions.
• Do not replace formal market research, advisory boards, or regulatory review processes.
• Are not guaranteed to reflect broader market consensus.

Client Users remain solely responsible for commercial, regulatory, and clinical decisions made based on the responses received.

Limitation of Liability

To the maximum extent permitted by law, Hummingbird Express disclaims all warranties, express or implied:

• Hummingbird Express is not liable for any indirect, consequential, or commercial losses arising from use of the Platform.
• Total liability is limited to the value of the relevant subscription purchased.

Nothing in these Terms excludes rights under Australian Consumer Law.

Modifications

Hummingbird Express reserves the right to amend these Terms at any time. Updated Terms will be published on the website and take effect immediately upon publication.

Termination

Hummingbird Express may suspend or terminate access if:

• Any User breaches these Terms.
• Content submitted is unlawful or unethical.
• An HCP status cannot be verified.

Governing Law

These Terms are governed by the laws of New South Wales, Australia. Any disputes shall be subject to the exclusive jurisdiction of Australian courts.

Nothing in these Terms excludes, restricts, or modifies any guarantees, warranties, or liabilities that cannot be excluded under the Australian Consumer Law.

Confidentiality, Privacy & Data Protection

All work conducted on this Platform is completed in compliance with the Privacy Act.

• User-submitted questions and responses are accessible only to authorised Hummingbird Insight staff for operational, quality control, and adverse event monitoring purposes.
• No other clients, HCPs (outside of those assigned), or third parties have access to submitted content.
• Responses are provided in de-identified format unless otherwise agreed in writing for adverse event reporting purposes.
• Users must not attempt to identify participating HCPs unless explicit written consent has been provided.

• By agreeing to participate Healthcare Professionals agree that they will treat all information provided, obtained and discussed as confidential and that they will not disclose it to any third party.
• Healthcare Professionals agree to destroy any stimulus material that has been provided to you for the research by Hummingbird or anyone acting on its behalf – you will not retain or disseminate this material to any other party.

A copy of our privacy policy can be found at: https://hummingbirdinsight.com.au/static/media/hummingbird-insight-privacy-policy-2017.151bd77d.pdf

Hummingbird Express will:

• Take reasonable steps to maintain confidentiality of User-submitted questions.
• Ensure HCP responses are de-identified.
• Not disclose confidential commercial information to third parties except as required by law.

Platform access controls: Multi-Factor Authentication (MFA) and Role-Based Access Controls (RBAC).

Security Controls: SOC 2 certified and GDPR Compliant. Survey data is transmitted over secure HTTPS/TLS channels, and sensitive information is encrypted in transit and at rest using industry-standard encryption protocols.

Adverse Event Monitoring and Reporting

Some clients have Adverse Event (“AE”) monitoring and reporting requirements.

In these cases, we must share with our client’s medical (pharmacovigilance) department details of any potential Adverse Events (AE), special situations, and product quality complaints, in relation to a patient potentially administered one of their products, mentioned during a ‘chat’. The information may be disclosed to local and overseas regulatory authorities or other third parties (such as those providing AE case processing activities, or license partners), for the purposes of meeting pharmacovigilance requirements. All other information you provide during the research will remain confidential.

Specifically in relation to that report, you may waive the confidentiality given to you under the Market Research Codes of Conduct and must indicate if you agree for our client’s pharmacovigilance team to contact you directly should they require additional information on the report.

During the sign-up process all Healthcare Professionals are offered a choice of sharing contact information with the client’s pharmacovigilance team (Name, email and phone) or remaining anonymous in the case of an adverse event. This choice can be changed at any time by updating in ‘my profile’ once logged in.

Question Design Responsibility

The design, framing, and regulatory compliance of submitted questions is solely the responsibility of the Client User.

Client Users are responsible for ensuring submitted questions comply with:

• Therapeutic Goods Administration (TGA) requirements
• Medicines Australia Code of Conduct (where applicable)
• Internal company compliance policies
• Any other applicable regulatory framework